Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Leukemia, acute myeloid (AML), adult
Results 1-25 of 322 for your search:
Start Over
Chemotherapy or Donor Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1227, NCI-2013-01746, CIR00000621, NA_00071844, NA_00071844 / CR00001237, NCT01588951
Azacitidine in Preventing Relapse in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: 2008-0503, NCI-2012-01259, NCI-2009-01513, NCT00887068
TK008: Efficacy Study on the Strategy of Herpes Simplex Virus Thymidine Kinase (HSV-Tk) Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TK008, NCI-2011-03649, 2009-012973-37, NCT00914628
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, NCT01041703
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
Phase: Phase III
Type: Supportive care
Age: 6 months to 21 years
Trial IDs: ACCL0934, NCI-2011-02636, CDR0000695661, COG-ACCL0934, NCT01371656
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients with Acute Myeloid Leukemia Who Are Undergoing Chemotherapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Age: 3 months to 30 years
Trial IDs: ACCL0933, NCI-2011-02640, CDR0000695748, COG-ACCL0933, NCT01307579
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981
Double Cord Versus Haploidentical (BMT CTN 1101)
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: BMTCTN1101, NCI-2014-00307, 2U10HL069294-11, 715, NCT01597778
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission
Phase: Phase III
Type: Treatment
Age: 55 and over
Trial IDs: CC-486-AML-001, NCI-2013-00084, 2012-003457-28, NCT01757535
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 116428, NCI-2014-01414, 2012-003438-18, NCT01767467
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine with or without Vorinostat in Treating Younger Patients with Previously Untreated Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 to 60
Trial IDs: S1203, NCI-2013-00490, PS1203_A06PAMDREVW01, SWOG-S1203, NCT01802333
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Phase: Phase III
Type: Treatment
Age: 65 and under
Trial IDs: CB-AB006, NCI-2013-00758, 2012-0166, NCT01854567
An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AC220-007, NCI-2014-00222, EudraCT Number 2013-004890-28, NCT02039726
Tretinoin and Arsenic Trioxide in Treating Patients with Untreated Acute Promyelocytic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: AAML1331, NCI-2014-02266, PAAML1331_A01PAMDREVW0, NCT02339740
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SGI-110-04, NCI-2015-00230, NCT02348489
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2215-CL-0301, NCI-2015-00931, 2015-000140-42, NCT02421939
A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: 0113-CL-1004, NCI-2013-01949, 2013-000903-18, NCT01877655
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 70
Trial IDs: 2005-0781, NCI-2011-02823, RP100469 02, NCT00498316
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OV06-001, NCI-2010-00051, NCT00709215
Azacitidine and Gemtuzumab Ozogamicin in Treating Patients with Relapsed Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 90
Trial IDs: 090516, NCI-2013-01963, Celgene - 090516, NCT00766116
Start Over